2 results
Approved WMORecruiting
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.